BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth — Live Feedhttps://www.live-feeds.com/feed/bms-doubles-up-with-pivotal-wins-in-lung-disease-solid-tumor-that-offer-hope-for-post-patent-cliff-growthContinuously updated, source-cited coverage. BMS lung disease, solid tumor drugs show promisehttps://www.live-feeds.com/feed/bms-doubles-up-with-pivotal-wins-in-lung-disease-solid-tumor-that-offer-hope-for-post-patent-cliff-growthhttps://www.live-feeds.com/feed/bms-doubles-up-with-pivotal-wins-in-lung-disease-solid-tumor-that-offer-hope-for-post-patent-cliff-growth#u124794Fri, 16 Oct 2026 03:02:49 +0000Bristol Myers Squibb's lung disease and solid tumor drugs have shown positive results in late-stage trials, offering hope for post-patent cliff growth. The company's lung disease drug succeeded at a lower dose, while a solid tumor drug also showed promise. This development could help BMS offset patent expirations and boost its pipeline.Why it mattersBMS is facing a patent cliff, with several key patents set to expire soon. The company is under pressure to deliver new growth drivers. The positive trial results could help BMS maintain its market position and provide new revenue streams